Molecular & Cellular Epilepsy

Molecular & Cellular Epilepsy is an open access, peer-reviewed, online journal that encompasses all basic and translational aspects of epilepsy and associated signaling pathways. Decades of experimental work have established an imbalance of excitation and inhibition as the leading mechanism of the transition from normal brain function to seizure. Molecular neuroanatomical techniques, high-throughput gene expression analyses, epigenetics, proteomics, and other new technologies are employed to investigate the molecular and cellular mechanisms of epilepsy and further define the molecular complexity that underlies seizure foci. By considering past and current advances in the field, this journal is expected to advance the understanding of molecular and cellular mechanisms underlying the development of epilepsy and further promote the development of novel therapeutic strategies. 

Topics of interest include but are not limited to the following areas:

  • The development of epilepsy
  • Initiation and termination of epileptic seizures
  • Cerebral damage caused by seizures and epilepsy
  • Neuronal excitability
  • CNS rhythm generation
  • Neurotransmitters
  • ion channels
  • Synaptic function 
  • Molecular and cellular imaging
  • Novel anti-epileptic drugs

 

Editors-in-Chief

  • Alberto Verrotti, MD
  • Department of Pediatrics, University of Perugia, Italy
  • Prof. Alberto Verrotti was born in Pescara, Italy, in June 13, 1959 and he graduated in Medicine in 1983; he specialized in Pediatrics and in Neurology. Actually, he is Associate Professor of Paediatrics, University of Perugia and Director, Department of Pediatrics, University of Perugia, Italy. His Main Research Interests are: Clinical trials with new antiepileptic drugs, Endocrine consequences of antiepileptic drugs, Preclinical markers of pharmacoresistance in epilepsy, Oxidative stress and metabolic disturbances in epilepsy, Cognitive impairment in epilepsy and Pediatric aspects of Headache. He is author of 365 papers in International Ranked Journals (Impact Factor: 670.381) He has been speaker at numerous International and National Congresses.

  • Yangmei Chen, M.D., Ph.D, Dean
  • Department of Neurology, Second Hospital, Chongqing Medical University, China

 

  • Deltev Boison, Ph.D.
  • Dow Chair of Neurology & Director of Neurobiology Research boison
  • Director of Basic and Translational Research
  • Basic and Translational Research Legacy Research Institute, Portland, Oregon, United States
  • The focus of my work is the brain’s endogenous anticonvulsant and neuroprotectant adenosine, which is a key homeostatic bioenergetic network regulator coupling receptor-mediated signaling pathways with epigenetic functions and mitochondrial bioenergetics. We try to understand how adenosine function and dysfunction contributes to normal and pathological brain function, respectively, and to translate these findings into novel therapeutic approaches. We study adenosine-related physiological and pathophysiological mechanisms in rodent models of disease and in mice with engineered mutations in adenosine metabolism or signaling. Bioengineered polymers, stem cell therapies, and gene therapies are used to afford therapeutic augmentation of the adenosine system. We apply these tools to study disease mechanisms and treatment options in epilepsy, traumatic brain injury, stroke, and schizophrenia. In addition to adenosine, we study the neuromodulatory role of glycine in the hippocampus within the context of epilepsy and schizophrenia.
 

Latest Articles


Vol 3 (2016)

Table of Contents